The future of drug pricing transparency

New England Journal of Medicine

11 February 2021 - A federal “Transparency in Coverage” rule requires insurers to disclose list prices and historical net prices for medications and to give patients personalised cost sharing estimates. 

Despite industry opposition, the rule may endure under the Biden administration.

Read New England Journal of Medicine Perspective

Michael Wonder

Posted by:

Michael Wonder